{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:51:10Z","timestamp":1790117470769,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00277-021-04693-8","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T18:42:34Z","timestamp":1633891354000},"page":"379-387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study"],"prefix":"10.1007","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9193-0059","authenticated-orcid":false,"given":"Oren","family":"Pasvolsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shai","family":"Shimony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Ram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avichai","family":"Shimoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liat","family":"Shargian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batia","family":"Avni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofir","family":"Wolach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzippy","family":"Shochat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Yerushalmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odelia","family":"Amit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Raanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Yeshurun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,9]]},"reference":[{"issue":"4","key":"4693_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Lowenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"issue":"22","key":"4693_CR2","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1001\/jama.2009.813","volume":"301","author":"J Koreth","year":"2009","unstructured":"Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Dohner H, Antin JH, Soiffer RJ, Cutler C (2009) Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 301(22):2349\u20132361. https:\/\/doi.org\/10.1001\/jama.2009.813","journal-title":"JAMA"},{"issue":"1","key":"4693_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","volume":"127","author":"JJ Cornelissen","year":"2016","unstructured":"Cornelissen JJ, Blaise D (2016) Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 127(1):62\u201370. https:\/\/doi.org\/10.1182\/blood-2015-07-604546","journal-title":"Blood"},{"key":"4693_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01247-4","author":"M Yanada","year":"2021","unstructured":"Yanada M (2021) The evolving concept of indications for allogeneic hematopoietic cell transplantation during first complete remission of acute myeloid leukemia. Bone Marrow Transplant. https:\/\/doi.org\/10.1038\/s41409-021-01247-4","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"4693_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Dohner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hajek R, Porkka K, Illes A, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW (2020) Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"issue":"8","key":"4693_CR6","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912\u20132919. https:\/\/doi.org\/10.1182\/blood-2005-05-2004","journal-title":"Blood"},{"issue":"12","key":"4693_CR7","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 15(12):1628\u20131633. https:\/\/doi.org\/10.1016\/j.bbmt.2009.07.004","journal-title":"Biol Blood Marrow Transplant"},{"key":"4693_CR8","unstructured":"Services UDoHaH (2017) Common terminology criteria for adverse events v5.0"},{"key":"4693_CR9","unstructured":"(CTCAE) [Internet] Princ Pract Clin Trial Med. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. 2021"},{"issue":"1","key":"4693_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, Chanswangphuwana C, Efebera YA, Holler E, Litzow M, Ordemann R, Qayed M, Renteria AS, Reshef R, Wolfl M, Chen YB, Goldstein S, Jagasia M, Locatelli F, Mielke S, Porter D, Schechter T, Shekhovtsova Z, Ferrara JL, Levine JE (2016) International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant 22(1):4\u201310. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.001","journal-title":"Biol Blood Marrow Transplant"},{"key":"4693_CR11","doi-asserted-by":"publisher","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME (2015) National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 21 (3):389\u2013401 e381. doi:https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001","DOI":"10.1016\/j.bbmt.2014.12.001"},{"key":"4693_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.critrevonc.2017.05.010","volume":"116","author":"AC Schuh","year":"2017","unstructured":"Schuh AC, Dohner H, Pleyer L, Seymour JF, Fenaux P, Dombret H (2017) Azacitidine in adult patients with acute myeloid leukemia. Crit Rev Oncol Hematol 116:159\u2013177. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.05.010","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"4693_CR13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19(2):202\u2013208. https:\/\/doi.org\/10.1038\/nm.3048","journal-title":"Nat Med"},{"key":"4693_CR14","doi-asserted-by":"publisher","first-page":"204062072098664","DOI":"10.1177\/2040620720986646","volume":"12","author":"I Aldoss","year":"2021","unstructured":"Aldoss I, Pullarkat V, Stein AS (2021) Venetoclax-containing regimens in acute myeloid leukemia. Ther Adv Hematol 12:2040620720986646. https:\/\/doi.org\/10.1177\/2040620720986646","journal-title":"Ther Adv Hematol"},{"key":"4693_CR15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1182\/blood-2019-127251","volume":"134","author":"W Keith","year":"2019","unstructured":"Keith W, Pratz CDD, Arellano ML, Letai AG, Thirman M, Pullarkat VA, Roboz GJ, Becker PS, Hong W-J, Jiang Qi, Hayslip J, Potluri J, Pollyea DA (2019) Outcomes after stem cell transplant in older patients with acute myeloid leukemia treated with venetoclax-based therapies. Blood 134:264. https:\/\/doi.org\/10.1182\/blood-2019-127251","journal-title":"Blood"},{"key":"4693_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26190","author":"A Apel","year":"2021","unstructured":"Apel A, Moshe Y, Ofran Y, Gural A, Wolach O, Ganzel C, Canaani J, Zektser M, Duek A, Stemer G, Hellman I, Basood M, Frisch A, Leibovitch C, Koren-Michowitz M (2021) Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.26190","journal-title":"Am J Hematol"},{"issue":"12","key":"4693_CR17","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1016\/j.bbmt.2020.08.027","volume":"26","author":"KS Sandhu","year":"2020","unstructured":"Sandhu KS, Dadwal S, Yang D, Mei M, Palmer J, Salhotra A, Al Malki M, Aribi A, Ali H, Khaled S, Forman SJ, Snyder D, Nakamura R, Stein AS, Marcucci G, Aldoss I, Pullarkat V (2020) Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myelogenous leukemia. Biol Blood Marrow Transplant 26(12):e322\u2013e327. https:\/\/doi.org\/10.1016\/j.bbmt.2020.08.027","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"4693_CR18","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","volume":"3","author":"AC Winters","year":"2019","unstructured":"Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, Kaiser J, Lyle L, Boggs C, Halsema K, Schowinsky JT, Rosser J, Ewalt MD, Siegele B, Rana V, Schuster S, Abbott D, Stevens BM, Jordan CT, Smith C, Pollyea DA (2019) Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv 3(20):2911\u20132919. https:\/\/doi.org\/10.1182\/bloodadvances.2019000243","journal-title":"Blood Adv"},{"issue":"2","key":"4693_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11864-019-0612-y","volume":"20","author":"Y Daneshbod","year":"2019","unstructured":"Daneshbod Y, Kohan L, Taghadosi V, Weinberg OK, Arber DA (2019) Prognostic significance of complex karyotypes in acute myeloid leukemia. Curr Treat Options Oncol 20(2):15. https:\/\/doi.org\/10.1007\/s11864-019-0612-y","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"4693_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1053\/j.seminoncol.2008.04.007","volume":"35","author":"K Mrozek","year":"2008","unstructured":"Mrozek K (2008) Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol 35(4):365\u2013377. https:\/\/doi.org\/10.1053\/j.seminoncol.2008.04.007","journal-title":"Semin Oncol"},{"issue":"45","key":"4693_CR21","doi-asserted-by":"publisher","first-page":"27882","DOI":"10.18632\/oncotarget.25328","volume":"9","author":"A Kuendgen","year":"2018","unstructured":"Kuendgen A, Muller-Thomas C, Lauseker M, Haferlach T, Urbaniak P, Schroeder T, Brings C, Wulfert M, Meggendorfer M, Hildebrandt B, Betz B, Royer-Pokora B, Gattermann N, Haas R, Germing U, Gotze KS (2018) Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature. Oncotarget 9(45):27882\u201327894. https:\/\/doi.org\/10.18632\/oncotarget.25328","journal-title":"Oncotarget"},{"issue":"9","key":"4693_CR22","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","volume":"103","author":"I Aldoss","year":"2018","unstructured":"Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM, Mei M, Salhotra A, Khaled S, Nakamura R, Snyder D, O\u2019Donnell M, Stein AS, Forman SJ, Marcucci G, Pullarkat V (2018) Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia. Haematologica 103(9):e404\u2013e407. https:\/\/doi.org\/10.3324\/haematol.2018.188094","journal-title":"Haematologica"},{"key":"4693_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1182\/blood-2020-138821","volume":"136","author":"A Daniel","year":"2020","unstructured":"Daniel A, Pollyea AW, Jordan CT, Smith C, Gutman JA (2020) Allogeneic transplant improves AML outcomes compared to maintenance venetoclax and azacitidine following response to initial venetoclax and azacitidine therapy. Blood 136:24. https:\/\/doi.org\/10.1182\/blood-2020-138821","journal-title":"Blood"},{"issue":"12","key":"4693_CR24","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.bbmt.2019.07.037","volume":"25","author":"A Candoni","year":"2019","unstructured":"Candoni A, Rambaldi A, Fanin R, Velardi A, Arcese W, Ciceri F, Lazzarotto D, Lussana F, Olivieri J, Grillo G, Parma M, Bruno B, Sora F, Bernasconi P, Saccardi R, Foa R, Sessa M, Bresciani P, Giglio F, Picardi A, Busca A, Sica S, Perruccio K, Zucchetti E, Diral E, Iori AP, Colombo AA, Tringali S, Santarone S, Irrera G, Mancini S, Zallio F, Malagola M, Albano F, Carella AM, Olivieri A, Tecchio C, Dominietto A, Vacca A, Sorasio R, Orciuolo E, Risitano AM, Leotta S, Cortelezzi A, Mammoliti S, Oldani E, Bonifazi F, Gitmo, (2019) Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with philadelphia chromosome-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors: a registry-based study of the Italian Blood and Marrow Transplantation Society (GITMO). Biol Blood Marrow Transplant 25(12):2388\u20132397. https:\/\/doi.org\/10.1016\/j.bbmt.2019.07.037","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"4693_CR25","doi-asserted-by":"publisher","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","volume":"118","author":"R Foa","year":"2011","unstructured":"Foa R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, Elia L, Paoloni F, Fazi P, Cimino G, Nobile F, Ferrara F, Castagnola C, Sica S, Leoni P, Zuffa E, Fozza C, Luppi M, Candoni A, Iacobucci I, Soverini S, Mandelli F, Martinelli G, Baccarani M, Party GALW (2011) Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 118(25):6521\u20136528. https:\/\/doi.org\/10.1182\/blood-2011-05-351403","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04693-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04693-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04693-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T04:03:32Z","timestamp":1641614612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04693-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,9]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["4693"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04693-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,9]]},"assertion":[{"value":"29 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}